VTRS stock icon

Viatris
VTRS
Market cap $13.8B

11.59 USD
+0.16
1.4%
At close Oct 4, 4:00 PM EDT
After hours
11.59
+0.00
0%
1 day
1.40%
5 days
0.17%
1 month
2.84%
3 months
9.24%
6 months
-1.36%
Year to date
1.76%
1 year
19.98%
5 years
-25.42%
 

About: Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.

Employees: 38,000

0
Funds holding %
of 6,728 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

35% more call options, than puts

Call options by funds: $35.7M | Put options by funds: $26.6M

0.85% more ownership

Funds ownership: 81.17% [Q1] → 82.02% (+0.85%) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 11 [Q1] → 11 (+0) [Q2]

1% less funds holding

Funds holding: 987 [Q1] → 978 (-9) [Q2]

9% less first-time investments, than exits

New positions opened: 87 | Existing positions closed: 96

10% less capital invested

Capital invested by funds: $11.5B [Q1] → $10.4B (-$1.12B) [Q2]

18% less repeat investments, than reductions

Existing positions increased: 314 | Existing positions reduced: 382

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target
$15
29%
upside
Avg. target
$15
29%
upside
High target
$15
29%
upside

1 analyst rating

positive
100%
neutral
0%
negative
0%
Jefferies
Glen Santangelo
56% 1-year accuracy
5 / 9 met price target
29%upside
$15
Buy
Reinstated
19 Jul 2024

Financial journalist opinion

Based on 5 articles about VTRS published over the past 30 days

Charts implemented using Lightweight Charts™